Suofeiya Home Collection (002572.SZ) forecasts a year-on-year increase in net profit for the year 2024 to be between 13.24 billion and 14.5 billion yuan, representing a growth of 5% to 15%.
Sofia (002572.SZ) issued a performance forecast for 2024, with an estimated full-year net profit attributable to shareholders of 13.24...
Suofeiya Home Collection (002572.SZ) released its performance forecast for the year 2024, expecting a net profit attributable to shareholders of 1.324 billion to 1.45 billion yuan, a year-on-year growth of 5%-15%. In 2024, the growth of custom furniture companies has slowed down due to the real estate cycle and intensified market competition. The company's operating environment faces short-term challenges, with a decrease in operating income compared to the same period last year in 2024. However, with the implementation of the government's policy to support the consumption of new products through trade-ins, the demand for home furnishings is expected to recover.
During the reporting period, the company continued to implement cost-cutting measures to improve efficiency, focusing on increasing productivity and controlling expenses, while further optimizing the debt structure, resulting in a significant decrease in financial expenses and profit indicators outperforming income indicators. In the reporting period, the company's wholly-owned subsidiary sold equity in a joint venture company and accepted the non-recurring gains and losses generated by the transaction price, with the estimated impact of non-recurring gains and losses on net profit for the year 2024 ranging from 229.3551 million yuan to 280.3229 million yuan, an increase from the same period last year, leading to an increase in net profit attributable to shareholders of the listed company compared to the same period last year.
Related Articles

Outlook for the US stock market in the third quarter of 2025 from CITIC Securities: The fundamentals still have resilience, short-term disturbances do not change the upward trend.

Tengshi and Fancheng Leopard continue to be bestsellers. BYD Company Limited (01211) high-end transformation welcomes "acceleration".

China's Outlook on Biopharmaceuticals in 2026: Innovation as the Theme, Breaking Through Overseas Markets and Commercial Insurance.
Outlook for the US stock market in the third quarter of 2025 from CITIC Securities: The fundamentals still have resilience, short-term disturbances do not change the upward trend.

Tengshi and Fancheng Leopard continue to be bestsellers. BYD Company Limited (01211) high-end transformation welcomes "acceleration".

China's Outlook on Biopharmaceuticals in 2026: Innovation as the Theme, Breaking Through Overseas Markets and Commercial Insurance.

RECOMMEND

Short Positions on Xiaomi (01810.HK) Surge 53% in a Week as Memory Price Spike Weighs on Sentiment
07/11/2025

Privatization Wave in Hong Kong Stocks: Exiting Liquidity Traps to Enable Strategic Transformation
07/11/2025

Over 30 Foreign Firms Attend Roundtable as Ministry of Commerce Signals Multiple Policy Shifts
07/11/2025


